Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.

Saved in:
Bibliographic Details
Title: Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Authors: Bornhäuser M; Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.; National Center for Tumor Diseases, Dresden, Germany., Schliemann C; Department of Medicine A, University Hospital Münster, Münster, Germany., Schetelig J; Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany., Röllig C; Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany., Kramer M; Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany., Glass B; Helios Klinikum, Berlin, Germany., Platzbecker U; Department for Hematology and Cellular Therapy, University Hospital, Leipzig, Germany., Burchert A; Department for Hematology and Oncology, University Hospital, Marburg, Germany., Hänel M; Medical Clinic III, Klinikum Chemnitz, Chemnitz, Germany., Müller LP; Department of Internal Medicine IV, University Hospital Halle Martin Luther, University Halle-Wittenberg, Halle, Germany., Klein S; University Hospital Mannheim, Mannheim, Germany., Bug G; Department of Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt, Germany., Beelen D; University Hospital Essen, Essen, Germany., Rösler W; Department of Hematology, Oncology, and Immunotherapy, University Hospital Erlangen, Erlangen, Germany., Schäfer-Eckart K; Klinikum Nürnberg, Paracelsus Medizinische Privatuniversität, Nuremberg, Germany., Schmid C; Department of Hematology, University Hospital Augsburg, Augsburg, Germany., Jost E; University Hospital Aachen, Aachen, Germany., Lenz G; Department of Medicine A, University Hospital Münster, Münster, Germany., Tischer J; University Hospital Munich-Grosshadern, Department of Internal Medicine III, Ludwig-Maximilian University Munich, Munich, Germany., Spiekermann K; University Hospital Munich-Grosshadern, Department of Internal Medicine III, Ludwig-Maximilian University Munich, Munich, Germany., Pfirrmann M; Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilian University Munich, Munich, Germany., Serve H; Department of Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt, Germany., Stölzel F; Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany., Alakel N; Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany., Middeke JM; Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany., Thiede C; Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany., Ehninger G; Medical Clinic I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany., Berdel WE; Department of Medicine A, University Hospital Münster, Münster, Germany., Stelljes M; Department of Medicine A, University Hospital Münster, Münster, Germany.
Source: JAMA oncology [JAMA Oncol] 2023 Apr 01; Vol. 9 (4), pp. 519-526.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2374-2445
DOI:10.1001/jamaoncol.2022.7605